Surgical Management of Endometriosis
1/1/2012 - Robert S. Schenken, MD
Editor: Roger P. Smith, MD
Endometriosis may be strongly suspected based on clinical presentation, but laparoscopy remains the gold standard for a definitive diagnosis. In patients with pain that is not improved with medical management, surgery affords an opportunity for both diagnosis and treatment. Surgical therapy may be conservative or definitive. Conservative therapy may include fulguration, laser ablation or excision of endometrial implants, lysis of adhesions, repair of tubal damage, uterosacral nerve ablation, and presacral neurectomy. Excision or ablation has been found to significantly reduce pain symptoms over laparoscopy alone, so endometriosis should be treated at the time of diagnosis. The decision to excise or ablate is based on the location of the lesion and the comfort level of the surgeon. There is no data showing superiority of one modality over the other. In patients with ovarian endometriomas, excision of the entire cyst wall should be performed. Incision and drainage or ablation is not recommended due to the three-fold higher rate of recurrence and reoperation. Pain relief is achieved in most patients who undergo laparoscopic ablation or resection of endometriosis and adhesiolysis. However, the risk of recurrence is estimated to be as high as 40 percent at 10 years follow-up and about 20 percent of patients will undergo additional surgery within two years.
Laparoscopic surgery and uterosacral nerve ablation (LUNA) disrupts the parasympathetic ganglia in the uterosacral ligaments, which carry pain signals from the uterus, cervix, and other pelvic structures. Randomized controlled trials have shown that LUNA at the time of laparoscopy does not decrease pain, dysmenorrhea, dysparunia, or dyschezia, so LUNA is not recommended. Presacral neurectomy (PSN) excises the presacral neural plexus, which carries pain signals from the uterus and cervix. A randomized controlled trial of laparoscopic surgery with or without PSN showed that the severity, but not the frequency of pelvic pain, dysmenorrhea, and dyspareunia was significantly less at 12 months in women undergoing PSN.
The term deep infiltrating endometriosis (DIE) describes infiltrative disease that involves the uterosacral ligaments, rectovaginal septum, bowel, ureters, or bladder. Medical therapy of symptomatic DIE is usually ineffective or transiently effective, with high recurrence rates. There is no consensus on the extent of resection necessary to treat DIE. Extensive dissection in the rectovaginal septum, rectal or bladder wall, or bowel resection is often necessary. Hysterectomy and bilateral salpingoophorectomy alone is inadequate for definitive therapy if endometriosis involving the bowel is left untreated.
Medical therapy after conservative surgery is recommended for patients with pelvic pain to reduce recurrence of pain and reoperation rates. First line therapies include either combined hormonal contraceptives or continuous progestins. Continuous combined hormonal contraceptives decrease recurrent dysmenorrhea for up to 24 months after surgery. Progestin therapy such as norethindrone acetate, depo medroxyprogesterone acetate (DMPA), and the levonorgestrel releasing intrauterine system (LNG-IUS) have all been shown to decrease pain recurrence rates.
Definitive surgical therapy (hysterectomy with or without bilateral salpingo-oophorectomy), should be reserved for women with severe symptoms who have completed childbearing. A retrospective analysis of patients undergoing hysterectomy for endometriosis showed higher rates of recurrent pain (62% vs. 11%) and need for reoperation (11% vs. 4%) in patients with retained ovarian tissue compared to those with bilateral oophorectomy. In premenopausal patients undergoing hysterectomy with bilateral oophorectomy for endometriosis, estrogen therapy (ET) is recommended to reduce symptoms of hypoestrogenism, reduce bone loss, and decrease cardiovascular morbidity. Starting ET immediately after surgery does not increase recurrence or reoperation rates.
American College of Obstetricians and Gynecologists [No Authors Listed]. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010 Jul;116(1):223-36. doi: 10.1097/AOG.0b013e3181e8b073.
Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24.
Initial Approval: January 2012, Reaffirmed: March 2018
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright © 2018 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.
Back to Search Results